Publications scientifiques Erasme

Publications scientifiques Erasme

  • Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study.

  • Auteurs Sitbon O, Sahay S, Escribano Subías P, Zolty RL, Kingrey JF, Ryan JJ, Sobol I, Sood N, Benza RL, Channick RN, Chin KM, Frantz RP, Ghofrani HA, Hemnes AR, McLaughlin VV, Vachiéry JL, Zamanian RT, Ter Veer A, Roscigno RF, Mottola D, Parsley E, Aranda R, Zisman LS, Howard LS
  • Revue Adv Ther
  • Date de publication 2025-08
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study.
  • The effects of lacosamide, pregabalin, and tapentadol on peripheral nerve excitability: A randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects.

  • Auteurs Nochi Z, Pia H, Bloms-Funke P, Boesl I, Caspani O, Chapman SC, di Pietro G, Fardo F, Genser B, Goetz M, Jiang B, Kostenko AV, Lebrun L, Leone CM, Li T, Möller-Grell N, Mouraux A, Pelz B, Pogatzki-Zahn E, Rong C, Schilder A, Schnetter E, Schubart K, Tracey I, Truini A, Vincent KF, Vollert J, Wanigasekera V, Wittayer M, Treede RD, Tankisi H, Finnerup NB
  • Revue Anesthesiology
  • Date de publication 2025-08
The effects of lacosamide, pregabalin, and tapentadol on peripheral nerve excitability: A randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects.
  • Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.

  • Auteurs Rossignol P, Zannad F, Massy Z, Azizi M, Chorfa F, Coadic J, Ferreira JP, Saraiva F, Mottier D, Guillemin F, Ngueyon Sime W, Bouali S, Rossignol B, Nortier J, Simon I, Robino C, Davin M, Bataille PM, Chantrel F, Castin N, Esnault V, Kazes I, Hannedouche T, Kamar N, Achard JM, Fenerol C, Achard-Hottelart C, Dimitrov Y, Girerd N, Maucourt-Boulch D, Frimat L
  • Revue Lancet
  • Date de publication 2025-08
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
Huderf hospital

Hôpital pédiatrique Reine Fabiola

Consultez toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola

Bordet hospital

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet

Decorative image of doctor and patient

Toutes les publications scientifiques du H.U.B.

Consultez toutes les publications scientifiques du H.U.B.